Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings)
In the preceding three months, 4 analysts have released ratings for Femasys (NASDAQ:FEMY), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Femasys, revealing an average target of $12.5, a high estimate of $13.00, and a low estimate of $12.00. Marking an increase of 4.17%, the current average surpasses the previous average price target of $12.00.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive Femasys is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Emily Bodnar | HC Wainwright & Co. | Maintains | Buy | $13.00 | $13.00 |
| Emily Bodnar | HC Wainwright & Co. | Maintains | Buy | $13.00 | $13.00 |
| Keay Nakae | Chardan Capital | Maintains | Buy | $12.00 | $12.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $12.00 | $10.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Femasys. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Femasys compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Femasys's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Femasys's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Femasys analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Femasys's Background
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Femasys's Economic Impact: An Analysis
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Femasys's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -7.77% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Femasys's net margin excels beyond industry benchmarks, reaching -1327.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Femasys's ROE excels beyond industry benchmarks, reaching -21.2%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Femasys's ROA excels beyond industry benchmarks, reaching -13.81%. This signifies efficient management of assets and strong financial health.
Debt Management: Femasys's debt-to-equity ratio is below the industry average at 0.44, reflecting a lower dependency on debt financing and a more conservative financial approach.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.